News | December 04, 2025
Briefs: Sun Pharma and Venus Remedies
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Here's a development that aims to keep your blood pressure in check. Literally!
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Patients can now get the starting 2.5 mg dose for $299 per month
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Subscribe To Our Newsletter & Stay Updated
